Duke University: Glioblastoma trials

The registry lists 37 Glioblastoma studies with Duke University as lead sponsor. 2 are open to participants now and 16 have results posted.

Early Phase 1 1Phase 1 5Phase 2 24No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Key Longitudinal Associations With Risk and Glioblastoma OutcomesRecruitingNCT06625684
• A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB TrialRecruitingNCT06069726Phase 2
• Bevacizumab Beyond Progression (BBP)CompletedNCT01740258Phase 2Results posted
• Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma PatientsCompletedNCT01738646Phase 2Results posted
• Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)TerminatedNCT01186406Phase 2Results posted
• Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for GlioblastomaCompletedNCT01004874Phase 2Results posted
• A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)TerminatedNCT00735436Phase 2Results posted
• Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma MultiformeCompletedNCT00672243Phase 2Results posted
• Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)CompletedNCT00671970Phase 2Results posted
• Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)CompletedNCT00615927Phase 2Results posted
• Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + IrinotecanCompletedNCT00613028Phase 2Results posted
• Ph II Bevacizumab + Etoposide for Pts w Recurrent MGCompletedNCT00612430Phase 2Results posted
• Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and GliosarcomasCompletedNCT00612339Phase 2Results posted
• Phase II Avastin + Bortezomib for Patients With Recurrent Malignant GliomaCompletedNCT00611325Phase 2Results posted
• Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBMCompletedNCT00597493Phase 2Results posted
• Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and GliosarcomasCompletedNCT00597402Phase 2Results posted
• Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant GliomaCompletedNCT00501891Phase 2Results posted
• Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive MeningiomaCompletedNCT00354913Phase 2Results posted
• Glioblastoma Psychosocial Support ProgramCompletedNCT06038604Not applicable
• GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBMSuspendedNCT05695976
• The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics EvaluationCompletedNCT04937413Early Phase 1
• Longitudinal Assessment of Marrow and Blood in Patients With GlioblastomaSuspendedNCT04657146
• Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating FieldsCompletedNCT03501134
• LITT Palliative Treatment for Patients With Malignant GliomasWithdrawnNCT03176160
• Effects of Steroid Tapering on Functional Capacity and NeurocognitionWithdrawnNCT01169415Not applicable
• A Panobinostat PresurgeryWithdrawnNCT01115036Phase 2
• Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + TemozolomideCompletedNCT00616005Phase 2
• Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant GliomaCompletedNCT00613093Phase 2
• Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBMCompletedNCT00612989Phase 1
• PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant GliomasCompletedNCT00612651Phase 1
• Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic GliomasCompletedNCT00612638Phase 1
• Ph I SU011248 + Irinotecan in Treatment of Pts w MGCompletedNCT00611728Phase 1
• Ph I Dasatinib + Erlotinib in Recurrent MGCompletedNCT00609999Phase 1
• Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00362921Phase 2
• Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma MultiformeWithdrawnNCT00046878Phase 2
• ZD 1839 in Treating Patients With Glioblastoma Multiforme in First RelapseCompletedNCT00016991Phase 2
• Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma MultiformeCompletedNCT00003464Phase 2